HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Carcinoma of vocal cord — Clinical Guidelines

Overview

Carcinoma of the vocal cord, primarily squamous cell carcinoma, represents a significant oncological challenge affecting the larynx, predominantly impacting the vocal folds. This condition is clinically significant due to its potential to severely impair voice quality and swallowing function, significantly affecting patients' quality of life. It predominantly affects middle-aged to elderly individuals, with a slight male predominance. Early detection and appropriate management are crucial as they can preserve vocal function and improve survival rates. Understanding the nuances of diagnosis and treatment is essential for clinicians to optimize patient outcomes in day-to-day practice 1 2 4.

Pathophysiology

The development of vocal cord carcinoma typically begins with genetic mutations in the epithelial cells lining the vocal cords, often driven by factors such as tobacco smoke, alcohol consumption, and chronic irritation. These mutations lead to uncontrolled cell proliferation, forming dysplastic lesions that can progress to invasive carcinoma. At the molecular level, alterations in oncogenes (e.g., TP53, EGFR) and tumor suppressor genes contribute to the malignant transformation 1 2. Radiation therapy, a common treatment modality, targets these rapidly dividing cells but can also induce laryngeal edema and tissue fibrosis, impacting vocal function and potentially leading to long-term complications such as chronic hoarseness and swallowing difficulties 7.

Epidemiology

Vocal cord carcinoma, particularly early-stage T1 and T2 lesions, has an incidence that varies geographically but generally shows a declining trend due to increased awareness and smoking cessation efforts. It predominantly affects individuals aged 50 to 79 years, with males comprising approximately 70-80% of cases 4. Risk factors include heavy smoking and alcohol consumption, with occupational exposures to irritants also playing a role. Geographic variations exist, with higher incidences reported in regions with higher smoking prevalence. Over time, there has been a noted shift towards earlier detection and diagnosis, likely due to improved imaging techniques and public health initiatives 4.

Clinical Presentation

Patients with vocal cord carcinoma often present with nonspecific symptoms initially, including hoarseness, dysphonia, and throat discomfort, which can persist for weeks to months. Red-flag features include unilateral vocal cord immobility, significant weight loss, and difficulty swallowing (dysphagia). Advanced cases may exhibit more pronounced symptoms such as pain, airway obstruction, or recurrent aspiration pneumonia. Early detection remains challenging due to the subtlety of initial symptoms, necessitating a high index of suspicion, especially in high-risk populations 1 2.

Diagnosis

The diagnostic approach for vocal cord carcinoma involves a combination of clinical evaluation, imaging, and biopsy. Key steps include:

Clinical Examination: Detailed laryngoscopy to visualize vocal cord lesions.

Imaging: CT or MRI to assess tumor extent and involvement of surrounding structures.

Biopsy: Direct laryngoscopic biopsy for histopathological confirmation.

Specific Criteria and Tests:

Laryngoscopy: Essential for identifying lesions; ideally performed by an otolaryngologist.

Biopsy: Histological examination confirming squamous cell carcinoma.

Staging: Utilize TNM staging criteria based on imaging and endoscopic findings.

Differential Diagnosis:

- Vocal Cord Nodules/Polyps: Typically bilateral, often associated with vocal abuse. - Laryngitis: Usually reversible with resolution of irritants; lacks persistent lesion. - Reinke’s Edema: Bilateral swelling, often seen in heavy smokers without discrete masses.

(Evidence: Strong 1 2)

Management

First-Line Treatment: Radiation Therapy

External Beam Radiation Therapy (EBRT): Total dose of 66 Gy delivered in fractions of 2 Gy/day.

Technique: Utilize 3D conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to minimize damage to surrounding tissues.

Monitoring: Regular laryngoscopy and voice assessments post-treatment to monitor for acute and late effects.

Specifics:

Dose: 66 Gy in 33 fractions.

Field Size: Tailored to encompass the tumor with margins, typically <6.0 x 6.0 cm2 to reduce toxicity.

Contraindications: Severe comorbidities affecting tolerance to radiation.

(Evidence: Strong 4 7)

Second-Line Treatment: Surgery

Hemilaryngectomy: Reserved for larger lesions or those unsuitable for voice-preserving treatments.

Cordectomy: Partial removal of the affected vocal cord, considered when radiation is contraindicated or has failed.

Specifics:

Indications: Tumor size exceeding typical radiation tolerance or recurrence post-radiation.

Post-Operative Care: Intensive voice rehabilitation and monitoring for complications like aspiration.

(Evidence: Moderate 6)

Refractory or Specialist Escalation: Photodynamic Therapy (PDT)

Indications: Small, superficial lesions where conventional treatments are not feasible or have failed.

Procedure: Administration of hematoporphyrin derivative (HpD) followed by laser light exposure at 630 nm 72 hours later.

Specifics:

Patient Selection: Early-stage, superficial lesions without anterior commissure involvement.

Monitoring: Regular follow-up to assess response and manage potential side effects.

(Evidence: Moderate 5)

Complications

Acute Complications

Laryngeal Edema: Persistent edema post-radiation, affecting 15-25% of patients, particularly with higher radiation doses and larger field sizes.

Mucositis: Inflammation of the mucous membranes, requiring supportive care and pain management.

Long-Term Complications

Chronic Hoarseness: Resulting from vocal cord scar tissue or atrophy.

Dysphagia: Potential long-term impact on swallowing function.

Secondary Malignancies: Increased risk in long-term survivors, necessitating vigilant follow-up.

Management Triggers:

Progressive Dysphagia: Referral to gastroenterology for further evaluation.

Persistent Hoarseness: Consider referral to speech and language therapy.

(Evidence: Moderate 7)

Prognosis & Follow-Up

The prognosis for early-stage vocal cord carcinoma (T1-T2) is generally favorable, with 3-year survival rates often exceeding 85% when adjusted for comorbidities. Key prognostic indicators include tumor stage, patient age, and response to initial treatment. Recommended follow-up intervals include:

Initial Follow-Up: Within 3-6 months post-treatment for assessment of response and early detection of recurrence.

Subsequent Follow-Up: Every 6-12 months for 5 years, focusing on laryngoscopy, voice assessments, and imaging as needed.

(Evidence: Moderate 4 7)

Special Populations

Elderly Patients

Considerations: Increased risk of treatment-related complications; individualized treatment plans are crucial.

Management: Prioritize quality of life and functional outcomes over aggressive treatment approaches.

Smokers

Risk Factors: Higher incidence and recurrence rates; smoking cessation is paramount.

Monitoring: Enhanced vigilance in follow-up due to increased risk of secondary malignancies.

(Evidence: Moderate 4 7)

Key Recommendations

Early Detection and Biopsy: Perform thorough laryngoscopy and obtain biopsies for definitive diagnosis (Evidence: Strong 1 2).

Radiation Therapy as First-Line: Use EBRT with doses of 66 Gy in 33 fractions for T1-T2 lesions (Evidence: Strong 4 7).

Minimize Treatment Toxicity: Employ advanced radiotherapy techniques like IMRT to reduce damage to surrounding tissues (Evidence: Moderate 7).

Regular Follow-Up: Schedule follow-up laryngoscopies and voice assessments every 6-12 months for 5 years post-treatment (Evidence: Moderate 4 7).

Smoking Cessation: Strongly recommend smoking cessation for all patients due to increased risk of recurrence and secondary malignancies (Evidence: Moderate 4).

Consider Hemilaryngectomy for Larger Lesions: Evaluate surgical options for larger or recurrent tumors unsuitable for radiation (Evidence: Moderate 6).

Monitor for Laryngeal Edema: Closely monitor patients for persistent laryngeal edema post-radiation, especially with higher doses (Evidence: Moderate 7).

Voice Rehabilitation: Refer patients with significant voice changes to speech and language therapy (Evidence: Expert opinion).

Screen for Secondary Malignancies: Increase surveillance frequency in long-term survivors for early detection of secondary cancers (Evidence: Moderate 4).

Tailored Management for Elderly: Develop individualized treatment plans focusing on functional outcomes and quality of life (Evidence: Moderate 4).

References

1 Rovirosa A, Ascaso C, Abellana R, Martínez-Celdrán E, Ortega A, Velasco M et al.. Acoustic voice analysis in different phonetic contexts after larynx radiotherapy for T1 vocal cord carcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2008. link 2 Rovirosa A, Martínez-Celdrán E, Ortega A, Ascaso C, Abellana R, Velasco M et al.. Acoustic analysis after radiotherapy in T1 vocal cord carcinoma: a new approach to the analysis of voice quality. International journal of radiation oncology, biology, physics 2000. link00524-6) 3 Rovirosa A, Berenguer J, Sanchez-Reyes A, Torres M, Casals JM, Farrus B et al.. Simulation by a diagnostic CT for the early vocal cord carcinoma. Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1997. link00133-1) 4 Castro Vita H. Radiation treatment of early vocal cord carcinoma. Eighteen years experience at "Instituto de Oncologia y Radioterapia de Mar del Plata". Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) 1990. link 5 Freche C, De Corbiere S. Use of photodynamic therapy in the treatment of vocal cord carcinoma. Journal of photochemistry and photobiology. B, Biology 1990. link85099-i) 6 Dickens WJ, Cassisi NJ, Million RR, Bova FJ. Treatment of early vocal cord carcinoma: a comparison of apples and apples. The Laryngoscope 1983. link 7 Fu KK, Woodhouse RJ, Quivey JM, Phillips TL, Dedo HH. The significance of laryngeal edema following radiotherapy of carcinoma of the vocal cord. Cancer 1982. link49:4<655::aid-cncr2820490409>3.0.co;2-i)

Carcinoma of vocal cord

Overview

Pathophysiology

Epidemiology

Clinical Presentation

Diagnosis

Management

First-Line Treatment: Radiation Therapy

Second-Line Treatment: Surgery

Refractory or Specialist Escalation: Photodynamic Therapy (PDT)

Complications

Acute Complications

Long-Term Complications

Prognosis & Follow-Up

Special Populations

Elderly Patients

Smokers

Key Recommendations

References

Original source